Transfusion support for haemoglobinopathies.

Area of Science:

• Hematology
• Transfusion Medicine
• Genetics

Background:

• Hemoglobinopathies, including sickle cell disease and thalassemia, necessitate careful blood transfusion management.
• Sickle cell disorders involve increased blood viscosity leading to vaso-occlusive crises, while thalassemias are characterized by ineffective erythropoiesis.
• Complications like iron overload (hemochromatosis) and hypersplenism require specific interventions.

Purpose of the Study:

• To review the indications and management strategies for blood transfusions in hemoglobinopathies.
• To compare the pathophysiology and transfusion requirements of sickle cell diseases and thalassemias.
• To explore novel transfusion technologies for improved patient outcomes.

Main Methods:

• Review of existing literature on blood transfusion in hemoglobinopathies.
• Analysis of pathophysiology and clinical manifestations of sickle cell disorders and thalassemias.
• Discussion of current and emerging transfusion techniques, including automated cell separation and neocyte transfusions.

Main Results:

• Transfusion therapy for sickle cell diseases is often episodic, focusing on managing crises and maintaining specific hemoglobin levels.
• Thalassemias require consistent hypertransfusion regimens to support growth and development, necessitating management of iron overload and potential splenectomy.
• Automated cell separation technologies enable the preparation of neocytes, which have longer survival rates, potentially reducing transfusion frequency.

Conclusions:

• Tailored transfusion strategies are essential for effective management of sickle cell diseases and thalassemias.
• Neocyte transfusions and advanced cell separation technologies represent promising advancements in hemoglobinopathy care.
• Integrated management including chelation therapy and timely splenectomy is critical for patients with hemoglobinopathies.